Last update 29 Jun 2024
Tandospirone Citrate
Last update 29 Jun 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms Metanopirone, Tandospirone, Tandospirone citrate (JAN/USAN) + [9] |
Target |
Mechanism 5-HT1A receptor agonists(Serotonin 1a (5-HT1a) receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (10 Jul 1996), |
Regulation- |
Login to view First Approval Timeline
Structure
Molecular FormulaC27H37N5O9 |
InChIKeyDMLGUJHNIWGCKM-DPFKZJTMSA-N |
CAS Registry112457-95-1 |
Related
35
Clinical Trials associated with Tandospirone Citrate枸橼酸坦度螺酮片在中国健康人群中空腹和餐后状态下单次给药的人体生物等效性临床试验
[Translation] A human bioequivalence clinical trial of tandospirone citrate tablets in Chinese healthy subjects after single administration under fasting and fed conditions
枸橼酸坦度螺酮片在健康受试者中单中心、开放、随机、单剂量、两制剂、两序列、四周期、完全重复空腹状态下的生物等效性试验
[Translation] A single-center, open, randomized, single-dose, two-formulation, two-sequence, four-cycle, completely repeated bioequivalence study of tandospirone citrate tablets in healthy subjects under fasting conditions
枸橼酸坦度螺酮片在健康受试者中单中心、开放、随机、单剂量、两制剂、两序列、四周期、完全重复餐后状态下的生物等效性试验
[Translation] A single-center, open-label, randomized, single-dose, two-formulation, two-sequence, four-cycle, fully repeated fed bioequivalence study of tandospirone citrate tablets in healthy subjects
100 Clinical Results associated with Tandospirone Citrate
Login to view more data
100 Translational Medicine associated with Tandospirone Citrate
Login to view more data
100 Patents (Medical) associated with Tandospirone Citrate
Login to view more data
255
Literatures (Medical) associated with Tandospirone Citrate24 Jan 2024Emergency medicine international
Retracted: Clinical Analysis on the Effects of Tandospirone Citrate Assisted by Drawing Therapy on Medication Compliance and Sleep Quality in Patients with Anxiety Disorders
Author: International, Emergency Medicine
[This retracts the article DOI: 10.1155/2022/9295627.].
01 Dec 2023Schizophrenia research. Cognition
Augmentation therapy with serotonin1A receptor partial agonists on neurocognitive function in schizophrenia: A systematic review and meta-analysis
Article
Author: Yokoi, Yuma ; Wada, Ayumu ; Stickley, Andrew ; Sumiyoshi, Tomiki ; Yamada, Risa
Background:
In a previous meta-analysis, the use of serotonin1A(5-HT1A) receptor partial agonists of the azapirone class as an add-on therapy was associated with beneficial effects on positive symptoms and attention/processing speed in schizophrenia patients. This meta-analysis builds on that study by examining the effects of adjunctive treatment with 5-HT1A partial agonists in improving other domains of neurocognitive function in schizophrenia patients.
Methods:
A literature search was performed from 1987 to May 2023 to identify randomized controlled trials. The standardized mean difference (SMD) with 95 % confidence intervals (CI) was calculated when there were two or more studies. Four studies, involving 313 patients, met the inclusion criteria and were used in the analysis.
Results:
5-HT1A partial agonists (buspirone or tandospirone) did not have a significant effect on verbal learning (SMD = 0.08, 95 % CI = -0.31 to 0.47) or working memory (SMD = 0.15, 95 % CI = -0.09 to 0.39). Regarding executive functions (Wisconsin Card Sorting Test), positive but non-significant results were seen with the category number (SMD = 0.26, 95 % CI = -0.81 to 1.32), while non-significant effects were noted for percent preservation errors (SMD = -0.10, 95 % CI = -0.53 to 0.33).
Conclusions:
The absence of any significant benefits in the cognitive domains studied here may have been due to the variance in the concomitant medication (typical vs atypical antipsychotic drugs), the level of cognition at baseline, or other factors. Further studies with various types of 5-HT1A agonists are warranted to examine the potential cognitive efficacy of stimulating these receptors.
01 Dec 2023Journal of psychiatric research
Comparison of tandospirone and escitalopram as a symptomatic treatment in Multiple System Atrophy-cerebellar ataxia: An open-label, non-controlled, 4 weeks observational study
Article
Author: Gao, Jing ; Quan, Meina ; Wang, Wei ; Jia, Jianping ; Guo, Dongmei ; Xu, Shuo
BACKGROUND:
Multiple system atrophy (MSA) is a neurodegenerative disorder characterized by autonomic failure and motor dysfunction in parkinsonism and/or cerebellar ataxia. Patients with MSA usually present with depression and anxiety symptoms. This observational study of patients with MSA-cerebellar subtype (MSA-C) with subthreshold depression/anxiety symptoms aimed to compare the efficacy of escitalopram oxalate (an antidepressant drug) and tandospirone citrate (an anxiolytic drug).
METHODS:
Fifty-six MSA-C patients were included, with 28 patients in each treatment group. One group received escitalopram oxalate 10 mg/day and the other group received tandospirone citrate 30 mg/day. The patients were evaluated at baseline and after 4 weeks. Several psychiatric and neurological tests were performed, including the Hamilton Anxiety Rating Scale (HAMA), Hamilton Depression Rating Scale (HAMD), Scale for the Assessment and Rating of Ataxia (SARA), and the Scale for Outcomes in Parkinson's Disease for Autonomic Symptoms (SCOPA-AUT). Furthermore, post-void residual urine volume (PVR) and blood pressure were measured.
RESULTS:
There was a more substantial reduction in the HAMA/HAMD, scores of stance, finger tracking, and finger nose test in the SARA, and PVR in the tandospirone group. There was a more substantial reduction in scores of dysuria, light-headed when standing up, syncope and hyperhidrosis in the SCOPA-AUT in the escitalopram group (p's < 0.05).
CONCLUSIONS:
Tandospirone citrate was more effective in improving depression/anxiety and some cerebellar ataxia symptoms, whereas escitalopram was more effective in improving some autonomic symptoms in MSA-C patients over a short-term period in an open-label observational study without a control group. Further research is needed to evaluate the long-term effects of tandospirone and escitalopram in MSA-C in long-term placebo controlled trials.
100 Deals associated with Tandospirone Citrate
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D01992 | Tandospirone Citrate |
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Anxiety | CN | 21 May 2003 | |
| Neurotic Disorders | JP | 10 Jul 1996 | |
| Psychophysiologic Disorders | JP | 10 Jul 1996 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Geographic Atrophy | Phase 3 | - | 01 Apr 2009 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 4 | 274 | High-dose tandospirone (60 mg/d) | swqnjdfffw(sxdribntsk) = empltuesut gmfplalfvk (yeflbjolce ) View more | - | 26 Feb 2023 | ||
Low-dose tandospirone (30 mg/d) | swqnjdfffw(sxdribntsk) = tkvhdkjhrv gmfplalfvk (yeflbjolce ) View more | ||||||
Phase 4 | 274 | 60 mg/day tandospirone | feqrufrakw(wrijegyoll) = zpcbsrxtxm yedhbxdnki (jbynziblzn ) | - | 01 Aug 2022 | ||
30 mg/day tandospirone | feqrufrakw(wrijegyoll) = rbepxvngao yedhbxdnki (jbynziblzn ) | ||||||
Phase 3 | 772 | (AL-8309B 1.0%) | vxjaqgfjql(wauibluupn) = tjykgjfptz xmexixgcmx (qrmzadqmet, zumglqylom - lopmqijasu) View more | - | 03 Jul 2014 | ||
(AL-8309B 1.75%) | vxjaqgfjql(wauibluupn) = ytkqbsonhc xmexixgcmx (qrmzadqmet, zerpexohwj - kojoogqyfm) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free